Treatment focus: discussed current and future treatments for osteoporosis, including the impact of anti-resorptive (e.g., bisphosphonates, denosumab) or anabolic therapies (e.g., parathyroid hormone analogues, anti-sclerostin antibodies) on bone-related outcomes in relation to genetic profiles or stratified patient groups. This evidence concerns the gene SOST and osteoporosis.